Showing 1501-1510 of 1576 results for "".
- EU Wraps Up Exploratory Talks With J&J to Secure Coronavirus Vaccinehttps://modernod.com/news/eu-wraps-up-exploratory-talks-with-jj-to-secure-coronavirus-vaccine/2478163/The European Commission said that it concluded exploratory talks with Johnson & Johnson to buy Ad26.COV2.S, the company’s vaccine candidate against COVID-19. Under the potential deal, once a vaccine has shown to be safe and effective against the novel coronavirus, the Commission s
- J&J Vaccine Protects Monkeys From Covid With Single Shothttps://modernod.com/news/jj-vaccine-protects-monkeys-from-covid-with-single-shot/2478099/Johnson & Johnson’s experimental coronavirus vaccine protected a group of macaques with a single shot in an early study, prompting the U.S. drugmaker to start trials in humans this month, according to a Bloomberg
- J&J Eyes Late-Stage Study Start of COVID-19 Vaccine in Septemberhttps://modernod.com/news/jj-eyes-late-stage-study-start-of-covid-19-vaccine-in-september/2478037/Johnson & Johnson disclosed alongside its second-quarter earnings call on Thursday that it hopes to begin a late-stage study of its COVID-19 vaccine candidate Ad26.COV2-S in late September, ahead of its previous schedule. The company is in talks with the US National Institutes of Health to br
- Interim 6-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosahttps://modernod.com/news/interim-6-month-data-of-rpgr-gene-therapy-shows-significant-vision-improvement-in-patients-living-with-x-linked-retinitis-pigmentosa/2478036/The Janssen Pharmaceutical Companies of Johnson & Johnson announced 6-month data from the ongoing phase 1/2 trial of its investigational gene therapy for the treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP). The interim data showed that low and intermediate doses of
- PRISM Vision Group Announces Agreement With The Retina Group of Washingtonhttps://modernod.com/news/prism-vision-group-announces-agreement-with-the-retina-group-of-washington-2/2477356/PRISM Vision Group announced an agreement to add its newest partner, The Retina Group of Washington (RGW), a provider of retinal and macular care in Washington, D.C., Virginia and Maryland. Terms of the deal were not disclosed. “Medicine is changing around us and over the past sever
- Prism Vision Group Announces Agreement With the Retina Group of Washingtonhttps://modernod.com/news/prism-vision-group-announces-agreement-with-the-retina-group-of-washington/2477344/Integrated eyecare services organization PRISM Vision Group announced an agreement to add The Retina Group of Washington (RGW), which provides retinal and macular care in Washington D.C., Virginia and Maryland. Terms of the deal were not disclosed. “Medicine is changing around us an
- EMA Grants Two Product Designations to Janssen’s RPGR Gene Therapy for X-Linked Retinitis Pigmentosahttps://modernod.com/news/ema-grants-two-product-designations-to-janssens-rpgr-gene-therapy-for-x-linked-retinitis-pigmentosa/2477338/The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Medicines Agency (EMA) has granted both PRIME (PRIority MEdicines) and Advanced Therapy Medicinal Product (ATMP) designations to the company’s adeno-associated virus (AAV)-RPGR gene t
- Fifteenth Annual Eyes on Capitol Hill Advocacy Eventhttps://modernod.com/news/fifteenth-annual-eyes-on-capitol-hill-advocacy-event/2477302/Prevent Blindness will be holding its 15th annual “Eyes on Capitol Hill” advocacy day on February 26, 2020, in Washington, D.C. The annual program provides those from across the United States the opportunity to meet with Congressional and Senate members, and their staff, to discuss vision issues
- Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseaseshttps://modernod.com/news/exonate-announces-collaboration-with-janssen-to-develop-a-new-eye-drop-for-the-treatment-of-retinal-vascular-diseases/2477223/Exonate, an early stage biotechnology company, announced that it has entered into a strategic collaboration agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Through the collaboration, Exonate will work with Janssen Research & Development scientists to develop an
- Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry AMDhttps://modernod.com/news/gemini-therapeutics-enrolls-first-patient-in-phase-1-study-of-gem103-for-dry-amd/2477214/Gemini Therapeutics announced it has initiated enrollment in its phase 1 study of GEM103, a recombinant, native Complement Factor H (CFH) for the treatment of dry age-related macular degeneration. AMD is the leading cause of irreversible blindness in the western world—affecting millions of